Nucleus RadioPharma, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2022

Location

Davidson NC US

Primary Industry

Healthcare

About

Based in New York, US, and founded by Eclipse Ventures and Mayo Clinic in collaboration, in 2022, Nucleus RadioPharma, Inc. operates as a healthcare platform that helps patients treat cancer through radiopharmaceuticals. In October 2023, Nucleus RadioPharma, Inc. raised USD 56 million in series A funding co-led by new investor GE Healthcare and returning investor Eclipse Ventures, with participation from other new investors Echo Global Logistics, Inc., Fox Chase Cancer Center, Granger Management, Mercy Health Pension Plan, and University of Missouri. Another returning investor Mayo Clinic Ventures also participated in the round. The company is working on radiopharmaceuticals for cancer patients by developing technologies for radiopharmaceutical clinical development, manufacturing, and supply chain. Radiopharmaceuticals have been an effective treatment tool across a variety of cancer types but it has inefficiencies across the development, manufacturing, and supply chain as of October 2022. Hence the firm aims to bring radiopharmaceutical treatments to the market at a cost, scale, and efficacy that would have maximal impact.

Current Investors

Mayo Clinic Ventures, Eclipse Ventures, GE Healthcare

Request a demo to show more

Primary Industry

Healthcare

Sub Industries

Oncology/Cancer Treatment

Website

www.nucleusrad.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.